Skip to main content

Specimen Collection Manual and Test Catalog

  or
  or
  or

PAIN MANAGEMENT DRUG PANEL, URINE W/ INTERPRETATION

Geisinger Epic Procedure Code:  LAB2803    Geisinger Epic ID:  43800

SPECIMEN COLLECTION
Specimen type: 

Random urine


Preferred collection container: 
Specimen required: 

15 mL aliquot AND 3 mL aliquot urine; minimum 10 mL and 1 mL, respectively.


Special notes: 

Urine temperature should be checked and within range (90-100° F) prior to submission. Orders must include the names of the drugs that require testing.



SPECIMEN PROCESSING
Transport temperature: 

Refrigerated (preferred) or room temperature.


Specimen stability: 

Room temperature: 2 days. Refrigerated: 14 days.


Rejection criteria: 

Stability limits exceeded.



TEST DETAILS
Additional information: 

The lab will perform urine validity testing, urine toxicology screen and other appropriate toxicology testing based on medication information provided. Screening results are presumptive and can only be used for medical purposes.


CPT code(s):  80307
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.

Test includes: 

Amphetamines screen
Benzodiazepines screen 
Cannabinoids screen
Cocaine metabolite screen 
Fentanyl screen 
Hydrocodone screen 
Methadone metabolite screen 
Morphine/Codeine screen 
Oxycodone screen 
Specimen Validity Testing
Testing interpretation. 
Based on the prescription information provided at order, confirmation by LC-MS/MS may be performed at an additional charge.


Methodology: 
EMIT
Homogeneous enzyme immunoassay
KIMS
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Synonyms: 

Compliance testing, OBCMTI


Clinical significance: 

PAIN MANAGEMENT DRUG PANEL, URINE and PAIN MANAGEMENT DRUG PANEL, URINE W/ INTERPRETATION are tests used to monitor the compliance of patients who are on opioids and benzodiazepines.


Doctoral Director(s): 
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM
Sheng-Ying (Margaret) Lo, PhD, DABCC
Review Date:  12/17/2024

Performing Locations